AI주식인사이트AI Stock Insight
C

차바이오텍

085660KOSDAQ기초 의약물질 제조업

44.5 / 100

Reference Date: 2026-04-13

Financial Score14.0 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Declined 10.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Cha BioTech primarily operates in umbilical cord blood storage, stem cell research, cell therapy development, anti-aging services, and consulting. The company also engages in pharmaceuticals, global CDMO, and international healthcare network expansion through its major subsidiaries. In 2024, revenue was distributed as 61.06% in medical services, 10.43% in product sales, and 28.51% in other services.

Number of Employees

354people

Average Salary

51.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 33.454.0Point
PBR
2.02Industry Average 2.034.0Point

In line with industry avg

ROE
-19.32Industry Average -4.293.5Point

4.5x industry avg (excellent)

Debt Ratio
51.30Industry Average 6.610.0Point

7.8x industry avg (risky)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲15.5% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼252.8% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -7.4% (declining, 3yr)

Detailed News Sentiment

7 totalPositive 1Neutral 3Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position5.0Point

52w mid range (56%)

Current 17,600Won52-week high 23,85052-week low 9,470
1-month return1.0Point

1m -10.93% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

9 totalPositive 0Neutral 9Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-01
  • Neutral주식등의대량보유상황보고서(일반)2026-04-01
  • Neutral[기재정정]사업보고서 (2025.12)2026-03-31
  • Neutral감사보고서제출2026-03-20
  • Neutral사업보고서 (2025.12)2026-03-20